Probenecid TRPV2 Agonist Therapy for Polycystic Kidney Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for polycystic kidney disease (PKD) are inadequate in reducing the severity and progression of the disease, as they fail to effectively target the underlying mechanisms of cyst formation and proliferation in renal cells.
Innovation Solution
Administration of TRPV2 agonists, such as probenecid, which increases intracellular calcium and inhibits cyst formation and proliferation by interacting with polycystin-2, potentially in combination with vasopressin receptor antagonists like tolvaptan, to reduce the severity and progression of PKD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for PKD are used, then the disease progression is slowed to some extent, but the severity reduction is inadequate and cyst formation continues
Solution Approach 1:
The patent changes the therapeutic parameter from conventional PKD treatments to TRPV2 channel agonists (probenecid), fundamentally altering the mechanism of action to achieve both severity reduction and cyst formation inhibition by targeting calcium signaling pathways in renal cells
Solution Approach 2:
The patent introduces TRPV2 channel activation as an intermediary mechanism that mediates the therapeutic effect, where probenecid acts as the intermediary substance that triggers calcium influx to inhibit cyst formation and reduce disease severity
2Productivity
If TRPV2 agonist (probenecid) is administered, then cyst size and proliferation are reduced, but the mechanism of action requires understanding of calcium signaling and polycystin-2 interaction
Solution Approach 1:
The patent leverages the body's existing TRPV2 calcium channels and polycystin-2 proteins, allowing the therapeutic agent to work through endogenous mechanisms rather than requiring external complex delivery systems or artificial pathways
3Reliability
If combination therapy with vasopressin receptor antagonist (tolvaptan) is used, then therapeutic efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges two distinct therapeutic mechanisms (TRPV2 agonism and vasopressin receptor antagonism) into a combination therapy regimen, where probenecid and tolvaptan work synergistically to enhance cyst reduction and disease severity control
Solution Approach 2:
The patent segments the therapeutic approach into two complementary mechanisms: probenecid targeting TRPV2 calcium channels for direct anti-cystogenic effects, and tolvaptan blocking vasopressin receptors to reduce fluid secretion into cysts
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Probenecid significantly reduces cyst size and proliferation in renal cells, demonstrating a therapeutic effect in both in vitro and in vivo models, with the combination of probenecid and tolvaptan showing enhanced efficacy in treating PKD.
Implementation Method 1
Administration of TRPV2 agonists, such as probenecid, which increases intracellular calcium and inhibits cyst formation and proliferation by interacting with polycystin-2
Data Source
AI summary
This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.